Top

Published in:

01-01-2011 | Epidemiology

A functional −77T>C polymorphism in XRCC1 is associated with risk of breast cancer

Authors: Li Liu, Peng Yuan, Li Liu, Chen Wu, Xiaomin Zhang, Huan Guo, Rong Zhong, Yihua Xu, Jing Wu, Shengyu Duan, Rui Rui, Tangchun Wu, Shaofa Nie, Xiaoping Miao, Dongxin Lin

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Abstract

X-ray repair cross-complementing 1 (XRCC1) plays a critical role in base excision repair and genetic variations of XRCC1 may be associated with cancer susceptibility. We tested this hypothesis by examining the contribution of polymorphism in the regulatory region of XRCC1 −77T>C to risk of breast cancer in 995 patients and 1,004 controls. We found this polymorphism was associated with an increased risk of breast cancer, with an OR of 1.25 (95% CI, 1.00–1.56) for the −77TC genotype and 2.55 (95% CI, 1.11–5.86) for the −77CC genotype compared with the −77TT genotype. Haplotype analysis combining the −77T>C with three well-studied non-synonymous polymorphisms (Arg194Trp, Arg280His, and Arg399Gln) showed that only the −77C-containing haplotype was associated with the risk. Moreover, the C allele had more than 3-fold decreased luciferase expression compared with the T allele in breast cancer cell line MCF-7 (P < 0.001). A meta-analysis of seven publications with a total 2,888 cancer cases and 3,177 controls demonstrated that −77C was significantly associated with cancer risk, with an OR of 1.34 (95% CI, 1.18–1.51) for the TC genotype and 1.53 (95% CI, 1.14–2.07) for the CC genotype compared with the TT genotype. In conclusion, these findings indicated that XRCC1 −77T>C polymorphism may be a genetic determinant for developing breast cancer.

Boyle P, Levin B (2008) World cancer report 2008. IARC, Lyon

Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168–183CrossRefPubMed

Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM (2009) Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat 117:409–416CrossRefPubMed

Wang QJ, Zhu WX, Xing XM (2006) Analysis of the incidence and survival of female breast cancer in Beijing during the last 20 years. Zhonghua Zhong Liu Za Zhi 28:208–210PubMed

Yang L, Li LD, Chen YD, Parkin DM (2006) Time trends, estimates and projects for breast cancer incidence and mortality in China. Zhonghua Zhong Liu Za Zhi 28:438–440PubMed

Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, This P, Asselain B, Stoppa-Lyonnet D, Fourquet A (2010) Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat 120:119–126CrossRefPubMed

Moullan N, Cox DG, Angele S, Romestaing P, Gerard JP, Hall J (2003) Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 12:1168–1174PubMed

Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366–374CrossRefPubMed

Mitra S, Boldogh I, Izumi T, Hazra TK (2001) Complexities of the DNA base excision repair pathway for repair of oxidative DNA damage. Environ Mol Mutagen 38:180–190CrossRefPubMed

10.

Cappelli E, Taylor R, Cevasco M, Abbondandolo A, Caldecott K, Frosina G (1997) Involvement of XRCC1 and DNA ligase III gene products in DNA base excision repair. J Biol Chem 272:23970–23975CrossRefPubMed

11.

Whitehouse CJ, Taylor RM, Thistlethwaite A, Zhang H, Karimi-Busheri F, Lasko DD, Weinfeld M, Caldecott KW (2001) XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell 104:107–117CrossRefPubMed

12.

Sterpone S, Cornetta T, Padua L, Mastellone V, Giammarino D, Testa A, Tirindelli D, Cozzi R, Donato V (2009) DNA repair capacity and acute radiotherapy adverse effects in Italian breast cancer patients. Mutat Res 684:43–48PubMed

13.

Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, Gregori D, DeMarchi M, Scagliotti GV (2007) Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13:2876–2881CrossRefPubMed

14.

Ladiges W, Wiley J, MacAuley A (2003) Polymorphisms in the DNA repair gene XRCC1 and age-related disease. Mech Ageing Dev 124:27–32CrossRefPubMed

15.

Shen MR, Jones IM, Mohrenweiser H (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58:604–608PubMed

16.

Narter KF, Ergen A, Agachan B, Gormus U, Timirci O, Isbir T (2009) Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). Anticancer Res 29:1389–1393PubMed

17.

Sturgis EM, Castillo EJ, Li L, Zheng R, Eicher SA, Clayman GL, Strom SS, Spitz MR, Wei Q (1999) Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 20:2125–2129CrossRefPubMed

18.

Duell EJ, Millikan RC, Pittman GS, Winkel S, Lunn RM, Tse CK, Eaton A, Mohrenweiser HW, Newman B, Bell DA (2001) Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Biomarkers Prev 10:217–222PubMed

19.

AC BC (2006) Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98:1382–1396CrossRef

20.

Hao B, Wang H, Zhou K, Li Y, Chen X, Zhou G, Zhu Y, Miao X, Tan W, Wei Q, Lin D, He F (2004) Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 64:4378–4384CrossRefPubMed

21.

Hao B, Miao X, Li Y, Zhang X, Sun T, Liang G, Zhao Y, Zhou Y, Wang H, Chen X, Zhang L, Tan W, Wei Q, Lin D, He F (2006) A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene 25:3613–3620CrossRefPubMed

22.

Moshynska O, Moshynskyy I, Misra V, Saxena A (2005) G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression. Oncogene 24:2042–2049CrossRefPubMed

23.

Soule HD, Vazguez J, Long A, Albert S, Brennan M (1973) A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51:1409–1416PubMed

24.

Ding K, Zhou K, He F, Shen Y (2003) LDA—a java-based linkage disequilibrium analyzer. Bioinformatics 19:2147–2148CrossRefPubMed

25.

Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425–434CrossRefPubMed

26.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed

27.

Kong YJ, Sun WX, Zhang YM, Shi YZ (2008) Relationships between the expressions of intercellular adhesion molecule-1 and tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 in lung tissues of patients with chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi 31:129–133PubMed

28.

Shu XO, Cai Q, Gao YT, Wen W, Jin F, Zheng W (2003) A population-based case-control study of the Arg399Gln polymorphism in DNA repair gene XRCC1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 12:1462–1467PubMed

29.

Jorgensen TJ, Helzlsouer KJ, Clipp SC, Bolton JH, Crum RM, Visvanathan K (2009) DNA repair gene variants associated with benign breast disease in high cancer risk women. Cancer Epidemiol Biomarkers Prev 18:346–350CrossRefPubMed

30.

Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229CrossRefPubMed

31.

Hu Z, Ma H, Lu D, Zhou J, Chen Y, Xu L, Zhu J, Huo X, Qian J, Wei Q, Shen H (2005) A promoter polymorphism (−77T>C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet Genomics 15:457–463CrossRefPubMed

32.

De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, Claes K, Velghe A, Van Meerbeeck J, Thierens H (2007) Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res 631:101–110PubMed

33.

Li M, Yin Z, Guan P, Li X, Cui Z, Zhang J, Bai W, He Q, Zhou B (2008) XRCC1 polymorphisms, cooking oil fume and lung cancer in Chinese women nonsmokers. Lung Cancer 62:145–151CrossRefPubMed

34.

Sterpone S, Mastellone V, Padua L, Novelli F, Patrono C, Cornetta T, Giammarino D, Donato V, Testa A, Cozzi R (2010) Single-nucleotide polymorphisms in BER and HRR genes, XRCC1 haplotypes and breast cancer risk in Caucasian women. J Cancer Res Clin Oncol 136:631–636CrossRefPubMed

35.

Brem R, Cox DG, Chapot B, Moullan N, Romestaing P, Gerard JP, Pisani P, Hall J (2006) The XRCC1 −77T>C variant: haplotypes, breast cancer risk, response to radiotherapy and the cellular response to DNA damage. Carcinogenesis 27:2469–2474CrossRefPubMed

36.

Misteli T, Soutoglou E (2009) The emerging role of nuclear architecture in DNA repair and genome maintenance. Nat Rev Mol Cell Biol 10:243–254CrossRefPubMed

37.

Yang M, Guo H, Wu C, He Y, Yu D, Zhou L, Wang F, Xu J, Tan W, Wang G, Shen B, Yuan J, Wu T, Lin D (2009) Functional FEN1 polymorphisms are associated with DNA damage levels and lung cancer risk. Hum Mutat 30:1320–1328CrossRefPubMed

38.

Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, Xu B, Lin D (2008) Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res 14:2878–2886CrossRefPubMed

39.

Chan KY, Liu W, Long JR, Yip SP, Chan SY, Shu XO, Chua DT, Cheung AN, Ching JC, Cai H, Au GK, Chan M, Foo W, Ngan HY, Gao YT, Ngan ES, Garcia-Barcelo MM, Zheng W, Khoo US (2009) Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women. J Med Genet 46:32–39CrossRefPubMed

40.

Lu J, Zhang S, Chen D, Wang H, Wu W, Wang X, Lei Y, Wang J, Qian J, Fan W, Hu Z, Jin L, Shen H, Huang W, Wei Q, Lu D (2009) Functional characterization of a promoter polymorphism in APE1/Ref-1 that contributes to reduced lung cancer susceptibility. FASEB J 23:3459–3469CrossRefPubMed

41.

Wang M, Wang M, Yuan L, Wu D, Zhang Z, Yin C, Fu G, Wei Q, Zhang Z (2010) A novel XPF −357A>C polymorphism predicts risk and recurrence of bladder cancer. Oncogene 29:1920–1928CrossRefPubMed

42.

Tebbs RS, Flannery ML, Meneses JJ, Hartmann A, Tucker JD, Thompson LH, Cleaver JE, Pedersen RA (1999) Requirement for the Xrcc1 DNA base excision repair gene during early mouse development. Dev Biol 208:513–529CrossRefPubMed

43.

Sak SC, Harnden P, Johnston CF, Paul AB, Kiltie AE (2005) APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res 11:6205–6211CrossRefPubMed

44.

Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH (2009) Differences in the expression profiles of excision repair crosscomplementation group 1, x-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival. J Thorac Oncol 4:1307–1312CrossRefPubMed

45.

Liu R, Yin LH, Pu YP (2007) Reduced expression of human DNA repair genes in esophageal squamous-cell carcinoma in china. J Toxicol Environ Health A 70:956–963CrossRefPubMed

46.

Vineis P, Manuguerra M, Kavvoura FK, Guarrera S, Allione A, Rosa F, Di Gregorio A, Polidoro S, Saletta F, Ioannidis JP, Matullo G (2009) A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. J Natl Cancer Inst 101:24–36PubMed

47.

Saadat M, Ansari-Lari M (2009) Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat 115:137–144CrossRefPubMed

48.

Geng J, Zhang YW, Huang GC, Chen LB (2008) XRCC1 genetic polymorphism Arg399Gln and gastric cancer risk: a meta-analysis. World J Gastroenterol 14:6733–6737CrossRefPubMed

49.

Naccarati A, Pardini B, Hemminki K, Vodicka P (2007) Sporadic colorectal cancer and individual susceptibility: a review of the association studies investigating the role of DNA repair genetic polymorphisms. Mutat Res 635:118–145CrossRefPubMed

Title: A functional −77T>C polymorphism in XRCC1 is associated with risk of breast cancer
Authors: Li Liu
Peng Yuan
Li Liu
Chen Wu
Xiaomin Zhang
Huan Guo
Rong Zhong
Yihua Xu
Jing Wu
Shengyu Duan
Rui Rui
Tangchun Wu
Shaofa Nie
Xiaoping Miao
Dongxin Lin
Publication date: 01-01-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0959-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer

Possible risk modifications in the association between MnSOD Ala-9Val polymorphism and breast cancer risk: subgroup analysis and evidence-based sample size calculation for a future trial

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer

Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis

The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer